October 24th 2024
For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can an Emerging PET Radiotracer Enhance Detection of Prostate Cancer Recurrence?
December 14th 2023The use of 68Ga-RM2 PET/MRI demonstrated a 35 percent higher sensitivity rate than MRI alone for the diagnosis of biochemical recurrence of prostate cancer, according to research recently presented at the Radiological Society of North America (RSNA) conference.
Can MRI-Guided Transurethral Ultrasound Ablation Have an Impact for Localized Prostate Cancer?
December 11th 2023Follow-up MRI imaging one year after transurethral ultrasound ablation revealed approximately 50 percent decreases in prostate volume and median PSA density, according to recently presented research findings at the 2023 Society of Urologic Oncology (SUO) Annual Meeting.
Can AI Improve Detection of Extraprostatic Extension on MRI?
December 4th 2023Utilizing a deep learning-based AI algorithm to differentiate between diagnostic and non-diagnostic quality of prostate MRI facilitated a 10 percent higher specificity rate for diagnosing extraprostatic extension on multiparametric MRI, according to research presented at the recent RSNA conference.
Seven Takeaways from Meta-Analysis of PSMA Radiotracers for Prostate Cancer Imaging
December 1st 2023In a newly published meta-analysis of 24 studies, researchers noted that the PSMA PET radiotracer 18F PSMA-1007 may provide more benefit than 68Ga Ga-PSMA-11 for primary staging of patients with prostate cancer and detection of local lesion recurrence, but also has drawbacks with higher liver uptake and multiple reports of false positive bone lesions.
Do Bone Scans Over Stage Prostate Cancer? What a Multicenter Study Reveals
November 16th 2023Fifty-seven percent of patients with prostate cancer diagnosed with osseous metastases on bone scans had negative findings on PSMA PET imaging, according to findings from an international multicenter comparative study.
Can MRI Findings Help Predict Toxicity After Radiotherapy for Prostate Cancer?
October 23rd 2023Emerging research findings suggest that a longer prostatic urethral length on MRI is associated with a 70 percent increased risk of grade >2 acute urinary toxicity after radiotherapy for prostate cancer.
Multinational Study Suggests High Variability with Quality of Prostate MRI
October 12th 2023In a study of 355 multiparametric prostate MRI exams from a total of 71 scanners from 41 facilities in 18 countries, researchers found that only 23 scanners achieved a PI-QUAL score of 5 for optimal image quality.
Emerging Insights in Diagnosing Recurrent Prostate Cancer in Men with Low PSA Levels
October 7th 2023In a recent video interview, Ashesh Jani, M.D., discussed a subset analysis from the SPOTLIGHT trial that examined the utility of the PET PSMA agent flotufolastat F 18 (Posluma) for detecting prostate cancer recurrence in men with low PSA levels lower than 1 ng/mL.
CMS Issues New Reimbursement Code for PSMA PET Agent POSLUMA
September 26th 2023The transitional pass-through payment reimbursement code for the FDA-approved PSMA PET agent for prostate cancer detection will be effective as of October 1, according to the Centers for Medicare and Medicare Services (CMS).
Can a Deep Learning Algorithm Enhance Detection of Prostate Cancer Recurrence with Biparametric MRI?
September 26th 2023For patients who had previous radiotherapy for prostate cancer (PCa), researchers found that a biparametric MRI-based deep learning model demonstrated an 81.5 percent sensitivity rate for PCa recurrence in patients previously treated with external beam radiation treatment (EBRT) and 100 percent sensitivity in patients with greater than 34 ml in gland volumes.
Study: PET/CT Multivariate Model Enhances Accuracy for Diagnosing Prostate Cancer
September 13th 2023For men with PSA scores between 4 to 10 ng/mL, a multivariate prediction model that incorporates 68Ga-PSMA PET/CT had a 92.7 AUC for predicting clinically significant prostate cancer, according to newly published research.
Study: 'All Men with PSAs Between 3 and 20 ng/mL Should Undergo MRI Before Biopsy'
September 7th 2023In a study of over 23,000 men who had PSA testing, researchers found that the adoption of pre-biopsy MRI resulted in a 21 percent decrease in negative biopsies and a 37 percent increase in the proportion of diagnosed Gleason score 7 to 10 prostate cancers.